China smartphone shipments slumped in June on inventory overhang: Jefferies
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), currently valued at $1.9 billion and trading near its 52-week low, announced the results of its 2025 Annual Meeting of Stockholders, which took place on March 12, 2025. According to InvestingPro data, the company’s stock has declined over 45% in the past year, reflecting ongoing market challenges. The meeting saw the approval of all proposed items, including the election of directors, advisory votes on executive compensation, and the frequency of future votes on such matters.
Shareholders voted in favor of electing eight directors to serve on the company’s Board of Directors until the next annual meeting. The directors elected were Christopher Anzalone, William Waddill, Michael Perry, Victoria Vakiener, Mauro Ferrari (NYSE:RACE), Adeoye Olukoton, Hongbo Lu, and Douglas Ingram. The voting results showed a significant majority in favor of each director, with the number of votes against and abstentions being notably smaller in comparison.
In addition to the board elections, an advisory vote on the compensation of Arrowhead’s named executive officers received approval, with 75,327,072 votes for, 7,389,926 against, and 153,176 abstaining. The non-binding nature of this vote reflects shareholders’ support for the company’s executive compensation practices.
Furthermore, shareholders endorsed the annual frequency for future advisory votes on executive compensation, with 79,893,615 votes for one year, 211,202 for two years, 2,466,302 for three years, and 299,055 abstentions.
The selection of KPMG LLP as the independent auditors for the fiscal year ended September 30, 2025, was ratified with a substantial majority of 100,977,999 votes for, 1,203,719 against, and 548,785 abstentions.
The participation level at the meeting was high, with 102,744,508 shares present in person or by proxy, out of the 125,073,046 shares outstanding as of the record date, January 17, 2025. While the company maintains strong liquidity with a current ratio of 6.09, InvestingPro analysis indicates the company is quickly burning through cash, with analysts not anticipating profitability this year. For deeper insights into Arrowhead’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
This information is based on the recent SEC filing by Arrowhead Pharmaceuticals, Inc. The company, based in Pasadena, California, specializes in pharmaceutical preparations and operates under the SIC code 2834. The company’s fiscal year ends on September 30. Looking ahead, InvestingPro reports that five analysts have revised their earnings upwards for the upcoming period, with the next earnings announcement expected on May 8, 2025. Subscribers to InvestingPro can access over 10 additional ProTips and extensive financial metrics for more informed investment decisions.
In other recent news, Arrowhead Pharmaceuticals has reported promising results from its Phase 1/2 clinical trial of ARO-C3, aimed at treating IgA nephropathy (IgAN), a kidney disease. The study demonstrated significant reductions in disease markers and proteinuria, with ARO-C3 achieving a mean sustained reduction of complement component 3 (C3) by over 87% through week 24. This news has prompted H.C. Wainwright to maintain a Buy rating for Arrowhead, with a price target of $80, highlighting the potential of ARO-C3 in complement-mediated diseases. Meanwhile, Goldman Sachs has reiterated a Neutral rating with a $26 price target, noting the need for longer-term data to evaluate the treatment’s full potential.
Arrowhead is also advancing its RNAi-based therapies for obesity, presenting preclinical data that supports the progression of ARO-INHBE and ARO-ALK7 into clinical trials. These treatments have shown impressive results in reducing body fat while preserving lean muscle mass in preclinical studies. Additionally, Arrowhead has launched a new website and white paper to support individuals with Familial Chylomicronemia Syndrome (FCS), providing educational resources and community engagement tools. This initiative underscores the company’s commitment to addressing rare diseases and supporting affected communities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.